PCSK9

Choose Selective PCSK9 Inhibitors

PCSK9 Products

All (5)
PCSK9 Inhibitors (4)
PCSK9 Antagonist (1)
New PCSK9 Products

Catalog No.	Product Name	Information	Product Use Citations
A2043^New	Evolocumab (anti-PCSK9)	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
E0116^New	PF-06446846 hydrochloride	PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0118	SBC-110736	SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
S8420	R-IMPP	R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S7976	SBC-115076	SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.	Front Cardiovasc Med, 2021, 8:746989 Menopause, 2020, 27(10):1155-1166 Journal of Second Military Medical University, 2019, 40(4): 412-419
A2043^New	Evolocumab (anti-PCSK9)	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
E0116^New	PF-06446846 hydrochloride	PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0118	SBC-110736	SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
S8420	R-IMPP	R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S7976	SBC-115076	SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.	Front Cardiovasc Med, 2021, 8:746989 Menopause, 2020, 27(10):1155-1166 Journal of Second Military Medical University, 2019, 40(4): 412-419
A2043^New	Evolocumab (anti-PCSK9)	Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
E0116^New	PF-06446846 hydrochloride	PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.